Schering Takes Aim At Glenmark Over Zetia

Law360, New York (March 29, 2007, 12:00 AM EDT) -- In the latest legal feud over a blockbuster cholesterol drug, Schering-Plough Corp. has hauled Glenmark Pharmaceuticals to court on allegations that the Indian generics maker has infringed a patent covering its anti-cholesterol treatment Zetia.

The lawsuit, filed last Thursday in the U.S. District Court for the District of New Jersey, was brought on behalf of Schering and MSP Singapore Co. LLC, Schering’s exclusive licensee for Zetia.

The complaint accuses the Mumbai-based Glenmark and its United States subsidiary of infringing on U.S. Patent No. RE37,721, which covers...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.